Objective:

To extend the labeled duration of use of the etonogestrel implant (Nexplanon) for pregnancy prevention from three years to up to five years.

Approach:

Key Findings:

• Nexplanon is effective for up to five years with no pregnancies reported during years 4 and 5.
• No new safety findings were observed during the extended use.
• Changes in menstrual bleeding patterns were the most common adverse reaction leading to discontinuation.

Interpretation:

The updated label for Nexplanon reflects its efficacy and safety for a broader range of women, including those with higher BMIs.

Limitations:

• The study was open-label and single-arm, which may introduce bias.
• The long-term effects beyond five years are not evaluated.

Conclusion:

Nexplanon is now approved for pregnancy prevention for up to five years, enhancing contraceptive options for women.

Sources:

• Organon
Source

Based on findings from:

FDA Extends Nexplanon Use

Kathryn Wighton. MDSpire News, 2026.

https://news.mdspire.com/obgyn/articles/fda-extends-nexplanon-use/

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.